{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:01:41Z","timestamp":1784772101037,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Epidemiol Glob Health"],"DOI":"10.1007\/s44197-026-00578-z","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:26:45Z","timestamp":1779334005000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of Infection Types, Pathogens, Antimicrobial Treatment, and Clinical Outcomes Data in Hospitalised Patients: Comprehensive Online Database for Antimicrobial Resistance (CODAR) Retrospective Pilot Study"],"prefix":"10.1007","volume":"16","author":[{"given":"Andy","family":"Townsend","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naglaa","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alona","family":"Kuraieva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristi","family":"Kuper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Passarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell","family":"Outlaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaughan","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neera","family":"Hobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Bond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Lee-Milner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuldeep","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravneet","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yashesh","family":"Paliwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Franco-Cendejas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Martin-Onra\u00ebt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Mosqueda-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Estrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Somily","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Felton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahableshwar","family":"Albur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"issue":"10369","key":"578_CR1","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"Global mortality associated","year":"2022","unstructured":"Global mortality associated. with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2022;400(10369):2221\u201348.","journal-title":"Lancet"},{"issue":"3","key":"578_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s00345-021-03913-0","volume":"40","author":"Z Zeng","year":"2022","unstructured":"Zeng Z, Zhan J, Zhang K, Chen H, Cheng S. Global, regional, and national burden of urinary tract infections from 1990 to 2019: an analysis of the global burden of disease study 2019. World J Urol. 2022;40(3):755\u201363.","journal-title":"World J Urol"},{"key":"578_CR3","doi-asserted-by":"publisher","first-page":"1145513","DOI":"10.3389\/fpubh.2023.1145513","volume":"11","author":"A Yakupu","year":"2023","unstructured":"Yakupu A, Aimaier R, Yuan B, Chen B, Cheng J, Zhao Y, et al. The burden of skin and subcutaneous diseases: findings from the global burden of disease study 2019. Front Public Health. 2023;11:1145513.","journal-title":"Front Public Health"},{"key":"578_CR4","doi-asserted-by":"publisher","unstructured":"Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS et al. The Microbiology of Bloodstream Infection: 20-Year Trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother. 2019;63(7). https:\/\/doi.org\/10.1128\/aac.00355-19","DOI":"10.1128\/aac.00355-19"},{"issue":"null","key":"578_CR5","doi-asserted-by":"publisher","first-page":"3425","DOI":"10.2147\/IDR.S325386","volume":"14","author":"J Pan","year":"2021","unstructured":"Pan J, Zhu Q, Zhang X, Xu J, Pan L, Mao X, et al. Factors Influencing the Prognosis of Patients with Intra-Abdominal Infection and Its Value in Assessing Prognosis. Infect Drug Resist. 2021;14(null):3425\u201332.","journal-title":"Infect Drug Resist"},{"issue":"5","key":"578_CR6","doi-asserted-by":"publisher","first-page":"863","DOI":"10.4103\/jfmpc.jfmpc_2257_22","volume":"12","author":"DJ Patil","year":"2023","unstructured":"Patil DJ, Vyas T, Kataria APS, Rajput R, Ashem A, Kumar M. Multi-centric clinic trials in evidence-based research - A narrative review on the Indian scenario. J Family Med Prim Care. 2023;12(5):863\u20137.","journal-title":"J Family Med Prim Care"},{"key":"578_CR7","unstructured":"World Health Organization. Global Antimicrobial Resistance and Use Surveillance System (GLASS). Available at: https:\/\/www.who.int\/initiatives\/glass [accessed 14 January 2025]."},{"issue":"7","key":"578_CR8","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13312-022-2561-y","volume":"59","author":"MK Das","year":"2022","unstructured":"Das MK. Multicenter Studies: Relevance, Design and Implementation. Indian Pediatr. 2022;59(7):571\u20139.","journal-title":"Indian Pediatr"},{"issue":"2","key":"578_CR9","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1080\/03007995.2020.1860922","volume":"37","author":"S Seifirad","year":"2021","unstructured":"Seifirad S, Alquran L. The bigger, the better? When multicenter clinical trials and meta-analyses do not work. Curr Med Res Opin. 2021;37(2):321\u20136.","journal-title":"Curr Med Res Opin"},{"key":"578_CR10","unstructured":"World Health Organization. WHO bacterial priority pathogens list. 2024. Available at: https:\/\/www.who.int\/publications\/i\/item\/9789240093461 [accessed 2 December 2024]."},{"issue":"4","key":"578_CR11","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1007\/s10096-025-05330-2","volume":"45","author":"A Mart\u00ednez-Mel\u00e9ndez","year":"2026","unstructured":"Mart\u00ednez-Mel\u00e9ndez A, Garza-Gonz\u00e1lez E, Del V\u00e1zquez-Larios R, Garibaldi-Rojas M, Martinez-Guerra M, Mireles-Davalos BA. The threat of multidrug-resistant microorganisms: active surveillance of key antimicrobial resistant pathogens in 2025 - a report from the INVIFAR network. Eur J Clin Microbiol Infect Dis. 2026;45(4):1041\u201357.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"578_CR12","doi-asserted-by":"crossref","unstructured":"Kuraieva A, Cabezas-Camarero G, Kiratisin P, Utt E. In Vitro Activity of Ceftaroline and Comparators against Bacterial Isolates Collected Globally from Patients with Skin and Soft Tissue Infections: ATLAS Program 2019\u20132020. Antibiotics (Basel). 2023;12(8).","DOI":"10.3390\/antibiotics12081237"},{"key":"578_CR13","doi-asserted-by":"publisher","first-page":"107268","DOI":"10.1016\/j.ijid.2024.107268","volume":"149","author":"X Yu","year":"2024","unstructured":"Yu X, Wang H, Ma S, Chen W, Sun L, Zou Z. Estimating the global and regional burden of lower respiratory infections attributable to leading pathogens and the protective effectiveness of immunization programs. Int J Infect Dis. 2024;149:107268.","journal-title":"Int J Infect Dis"},{"key":"578_CR14","doi-asserted-by":"publisher","unstructured":"Zhou Y, Zhou Z, Zheng L, Gong Z, Li Y, Jin Y et al. Urinary Tract Infections Caused by Uropathogenic Escherichia coli: Mechanisms of Infection and Treatment Options. Int J Mol Sci. 2023;24(13). https:\/\/doi.org\/10.3390\/ijms241310537","DOI":"10.3390\/ijms241310537"},{"key":"578_CR15","unstructured":"NHS England. New awareness campaign to help reduce hospital admissions for urinary tract infections. Available at: https:\/\/www.england.nhs.uk\/2023\/10\/new-awareness-campaign-to-help-reduce-hospital-admissions-for-urinary-tract-infections\/ Accessed on 16 December 2025."},{"issue":"1","key":"578_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1017\/S095026881700259X","volume":"146","author":"A Rosello","year":"2018","unstructured":"Rosello A, Pouwels KB, Domenech DECM, Hayward EVANK, Hopkins AC. Seasonality of urinary tract infections in the United Kingdom in different age groups: longitudinal analysis of The Health Improvement Network (THIN). Epidemiol Infect. 2018;146(1):37\u201345.","journal-title":"Epidemiol Infect"},{"key":"578_CR17","unstructured":"Understanding the burden of UTI hospitalisations in England. UK Health Security Agency. https:\/\/www.gov.uk\/government\/publications\/understanding-the-burden-of-uti-hospitalisations-in-england\/understanding-the-burden-of-uti-hospitalisations-in-england"},{"key":"578_CR18","unstructured":"GOV. UK. Point prevalence survey on healthcareassociated infections, antimicrobial use and antimicrobial stewardship in England. 2023. Available at: https:\/\/assets.publishing.service.gov.uk\/media\/6827325d010c5c28d1c7e728\/HCAI-AMU-PPS-2023-report.pdf. [accessed on 4 December 2025]."},{"key":"578_CR19","doi-asserted-by":"publisher","unstructured":"Edwards L, Pickett J, Ashcroft DM, Dambha-Miller H, Majeed A, Mallen C et al. UK research data resources based on primary care electronic health records: review and summary for potential users. BJGP Open. 2023;7(3). https:\/\/doi.org\/10.3399\/BJGPO.2023.0057","DOI":"10.3399\/BJGPO.2023.0057"},{"issue":"10","key":"578_CR20","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/j.clinthera.2021.09.002","volume":"43","author":"R Jhaveri","year":"2021","unstructured":"Jhaveri R, John J, Rosenman M. Electronic Health Record Network Research in Infectious Diseases. Clin Ther. 2021;43(10):1668\u201381.","journal-title":"Clin Ther"},{"key":"578_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ijid.2020.09.1481","volume":"101","author":"A Alothman","year":"2020","unstructured":"Alothman A, Al Thaqafi A, Al Ansary A, Zikri A, Fayed A, Khamis F, et al. Prevalence of infections and antimicrobial use in the acute-care hospital setting in the Middle East: Results from the first point-prevalence survey in the region. Int J Infect Dis. 2020;101:249\u201358.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"578_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.37201\/req\/057.2020","volume":"33","author":"E Bouza","year":"2020","unstructured":"Bouza E, Brenes FJ, D\u00edez Domingo J, Eiros Bouza JM, Gonz\u00e1lez J, Gracia D, et al. The situation of infection in the elderly in Spain: a multidisciplinary opinion document. Rev Esp Quimioter. 2020;33(5):327\u201349.","journal-title":"Rev Esp Quimioter"},{"key":"578_CR23","doi-asserted-by":"crossref","unstructured":"Garcia MP, V\u00e1zquez O, Duran J, Horcajada JP, Almendral A, Porr\u00f3n R et al. Trends in point-prevalence studies of healthcare associated infections in long-term care facilities: A nationwide surveillance program in Catalonia, Spain (2013\u20132022). Enfermedades infecciosas y microbiologia clinica (English ed). 2025;43:S11-S8.","DOI":"10.1016\/j.eimce.2024.11.005"},{"key":"578_CR24","unstructured":"GOV.UK. Flu vaccination programme 2025 to 2026: information for healthcare practitioners. Available at: https:\/\/www.gov.uk\/government\/publications\/flu-vaccination-programme-information-for-healthcare-practitioners\/flu-vaccination-programme-2023-to-2024-information-for-healthcare-practitioners [accessed 3 December 2025]."},{"key":"578_CR25","unstructured":"GOV.UK. Confronting antimicrobial resistance 2024 to 2029. Available at: https:\/\/www.gov.uk\/government\/publications\/uk-5-year-action-plan-for-antimicrobial-resistance-2024-to-2029\/confronting-antimicrobial-resistance-2024-to-2029 [accessed 3 December 2025]."},{"key":"578_CR26","doi-asserted-by":"publisher","unstructured":"Koya SF, Ganesh S, Selvaraj S, Wirtz VJ, Galea S, Rockers PC. Consumption of systemic antibiotics in India in 2019. Lancet Reg Health - Southeast Asia. 2022;4. https:\/\/doi.org\/10.1016\/j.lansea.2022.100025","DOI":"10.1016\/j.lansea.2022.100025"},{"key":"578_CR27","doi-asserted-by":"publisher","unstructured":"Zhang S, Liao X, Ding T, Ahn J. Role of \u03b2-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. Antibiot (Basel). 2024;13(3). https:\/\/doi.org\/10.3390\/antibiotics13030260","DOI":"10.3390\/antibiotics13030260"},{"issue":"6","key":"578_CR28","doi-asserted-by":"publisher","first-page":"e619","DOI":"10.1016\/S2214-109X(18)30186-4","volume":"6","author":"A Versporten","year":"2018","unstructured":"Versporten A, Zarb P, Caniaux I, Gros MF, Drapier N, Miller M, et al. Antimicrobial consumption and resistance in adult hospital inpatients in 53 countries: results of an internet-based global point prevalence survey. Lancet Glob Health. 2018;6(6):e619\u201329.","journal-title":"Lancet Glob Health"},{"issue":"2","key":"578_CR29","doi-asserted-by":"publisher","first-page":"105035","DOI":"10.1016\/j.cmicom.2024.105035","volume":"1","author":"M Sharland","year":"2024","unstructured":"Sharland M, Cook A, Pouwels KB, McDonnell A, Laxminarayan R, Hope W, et al. Universal access to key essential antibiotics\u2014Recent amoxicillin global shortages mask a wider policy failure. CMI Commun. 2024;1(2):105035.","journal-title":"CMI Commun"},{"key":"578_CR30","unstructured":"GOV.UK. Antibiotic \u2018Access\u2019 list updated for the UK. Available at: https:\/\/www.gov.uk\/government\/news\/antibiotic-access-list-updated-for-the-uk#:~:text=Amoxicillin%2Fclavulanic%20acid%20is%20an,bacteria%20compared%20to%20other%20antibiotics. [accessed 31 January 2025]."},{"issue":"3","key":"578_CR31","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jhin.2019.05.014","volume":"103","author":"SK Singh","year":"2019","unstructured":"Singh SK, Sengupta S, Antony R, Bhattacharya S, Mukhopadhyay C, Ramasubramanian V, et al. Variations in antibiotic use across India: multi-centre study through Global Point Prevalence survey. J Hosp Infect. 2019;103(3):280\u20133.","journal-title":"J Hosp Infect"},{"key":"578_CR32","doi-asserted-by":"publisher","first-page":"103175","DOI":"10.1016\/j.eclinm.2025.103175","volume":"82","author":"S Bhattacharjee","year":"2025","unstructured":"Bhattacharjee S, Mothsara C, Shafiq N, Panda PK, Rohilla R, Kaore SN, et al. Antimicrobial prescription patterns in tertiary care centres in India: a multicentric point prevalence survey. eClinicalMedicine. 2025;82:103175.","journal-title":"eClinicalMedicine"},{"key":"578_CR33","doi-asserted-by":"crossref","unstructured":"M S, M KK. Expert Opinion on the Prescription Practice of Carbapenem Antibiotics for the Treatment of Drug-Resistant Bacterial Infections in Indian Settings. Asian J Res Infect Dis. 2024;15(3):26\u201332.","DOI":"10.9734\/ajrid\/2024\/v15i3335"},{"key":"578_CR34","doi-asserted-by":"publisher","unstructured":"S M, M KK. Expert perspectives on the clinical use of meropenem monotherapy in the management of various antibiotic-resistant pathogens in Indian settings. Int J Sci Rep. 2025;11(2):60\u20135. https:\/\/doi.org\/10.18203\/issn.2454-2156.IntJSciRep20250056","DOI":"10.18203\/issn.2454-2156.IntJSciRep20250056"},{"issue":"3","key":"578_CR35","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.jclinepi.2013.09.021","volume":"67","author":"A Prados-Torres","year":"2014","unstructured":"Prados-Torres A, Calder\u00f3n-Larra\u00f1aga A, Hancco-Saavedra J, Poblador-Plou B, van den Akker M. Multimorbidity patterns: a systematic review. J Clin Epidemiol. 2014;67(3):254\u201366.","journal-title":"J Clin Epidemiol"},{"issue":"9","key":"578_CR36","doi-asserted-by":"publisher","first-page":"e008880","DOI":"10.1136\/bmjgh-2022-008880","volume":"7","author":"Z Xinyi","year":"2022","unstructured":"Xinyi Z, Asutosh P, Ting W, Shangzhi X, Jie Y, Pengpeng Y, et al. Community prevalence and dyad disease pattern of multimorbidity in China and India: a systematic review. BMJ Global Health. 2022;7(9):e008880.","journal-title":"BMJ Global Health"},{"issue":"2","key":"578_CR37","first-page":"205","volume":"71","author":"N Garin","year":"2015","unstructured":"Garin N, Koyanagi A, Chatterji S, Tyrovolas S, Olaya B, Leonardi M, et al. Global Multimorbidity Patterns: A Cross-Sectional, Population-Based, Multi-Country Study. Journals Gerontology: Ser A. 2015;71(2):205\u201314.","journal-title":"Journals Gerontology: Ser A"},{"key":"578_CR38","doi-asserted-by":"publisher","first-page":"101044","DOI":"10.1016\/j.molmet.2020.101044","volume":"39","author":"S Erener","year":"2020","unstructured":"Erener S. Diabetes, infection risk and COVID-19. Mol Metabolism. 2020;39:101044.","journal-title":"Mol Metabolism"},{"issue":"7","key":"578_CR39","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1007\/s00125-024-06102-x","volume":"67","author":"RIG Holt","year":"2024","unstructured":"Holt RIG, Cockram CS, Ma RCW, Luk AOY. Diabetes and infection: review of the epidemiology, mechanisms and principles of treatment. Diabetologia. 2024;67(7):1168\u201380.","journal-title":"Diabetologia"},{"issue":"4","key":"578_CR40","doi-asserted-by":"publisher","first-page":"e70059","DOI":"10.1111\/liv.70059","volume":"45","author":"G Targher","year":"2025","unstructured":"Targher G, Tilg H, Valenti L. Risk of Serious Bacterial and Non-Bacterial Infections in People With MASLD. Liver Int. 2025;45(4):e70059.","journal-title":"Liver Int"},{"issue":"10159","key":"578_CR41","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/S0140-6736(18)31694-5","volume":"392","author":"KJ Foreman","year":"2018","unstructured":"Foreman KJ, Marquez N, Dolgert A, Fukutaki K, Fullman N, McGaughey M, et al. Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: reference and alternative scenarios for 2016\u201340 for 195 countries and territories. Lancet. 2018;392(10159):2052\u201390.","journal-title":"Lancet"},{"issue":"3","key":"578_CR42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.37201\/req\/134.2022","volume":"36","author":"M Mir\u00f3n-Rubio","year":"2023","unstructured":"Mir\u00f3n-Rubio M, Parra Jord\u00e1n JJ, Gonz\u00e1lez Ramallo VJ, Mujal Mart\u00ednez A, Fern\u00e1ndez Muix\u00ed J, Iglesias Gallego M, et al. Economic burden of skin and skin structure infections due to Gram-positive bacteria in patients on hospital at home-based outpatient parenteral antibiotic therapy (OPAT). Rev Esp Quimioter. 2023;36(3):291\u2013301.","journal-title":"Rev Esp Quimioter"},{"issue":"1","key":"578_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s13017-024-00551-w","volume":"19","author":"M Sartelli","year":"2024","unstructured":"Sartelli M, Tascini C, Coccolini F, Dellai F, Ansaloni L, Antonelli M, et al. Management of intra-abdominal infections: recommendations by the Italian council for the optimization of antimicrobial use. World J Emerg Surg. 2024;19(1):23.","journal-title":"World J Emerg Surg"},{"issue":"5","key":"578_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1089\/sur.2019.276","volume":"21","author":"BL Xie","year":"2020","unstructured":"Xie BL, Guo RS, Yang XW, Wan L, Yao WY, Lai Q, et al. Epidemiology and Drug Resistance Analysis of Mixed Infection in Orthopedic Surgical Sites. Surg Infect (Larchmt). 2020;21(5):465\u201371.","journal-title":"Surg Infect (Larchmt)"},{"issue":"10","key":"578_CR45","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.4240\/wjgs.v15.i10.2320","volume":"15","author":"SR Song","year":"2023","unstructured":"Song SR, Liu YY, Guan YT, Li RJ, Song L, Dong J, et al. Timing of surgical operation for patients with intra-abdominal infection: A systematic review and meta-analysis. World J Gastrointest Surg. 2023;15(10):2320\u201330.","journal-title":"World J Gastrointest Surg"},{"issue":"10325","key":"578_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray CJL, Ikuta KS, Sharara F, Swetschinski L, Robles Aguilar G, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629\u201355.","journal-title":"Lancet"},{"issue":"8","key":"578_CR47","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1111\/j.1751-7176.2008.08172.x","volume":"10","author":"RE Schmieder","year":"2008","unstructured":"Schmieder RE, Ruilope LM. Blood pressure control in patients with comorbidities. J Clin Hypertens (Greenwich). 2008;10(8):624\u201331.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"10","key":"578_CR48","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","volume":"26","author":"ZA Shyr","year":"2021","unstructured":"Shyr ZA, Cheng YS, Lo DC, Zheng W. Drug combination therapy for emerging viral diseases. Drug Discov Today. 2021;26(10):2367\u201376.","journal-title":"Drug Discov Today"},{"issue":"3","key":"578_CR49","doi-asserted-by":"publisher","first-page":"1700582","DOI":"10.1183\/13993003.00582-2017","volume":"50","author":"A Torres","year":"2017","unstructured":"Torres A, Niederman MS, Chastre J, Ewig S, Fernandez-Vandellos P, Hanberger H, et al. International ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia. Eur Respir J. 2017;50(3):1700582.","journal-title":"Eur Respir J"},{"issue":"1","key":"578_CR50","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1186\/s13643-024-02695-x","volume":"13","author":"C Lai","year":"2024","unstructured":"Lai C, Ma Z, Zhang J, Wang J, Wang J, Wu Z, et al. Efficiency of combination therapy versus monotherapy for the treatment of infections due to carbapenem-resistant Gram-negative bacteria: a systematic review and meta-analysis. Syst Rev. 2024;13(1):309.","journal-title":"Syst Rev"},{"issue":"10","key":"578_CR51","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/pathogens10101310","volume":"10","author":"G Mancuso","year":"2021","unstructured":"Mancuso G, Midiri A, Gerace E, Biondo C. Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens. 2021;10(10):1310.","journal-title":"Pathogens"},{"issue":"3","key":"578_CR52","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.tibtech.2012.12.006","volume":"31","author":"RJ Worthington","year":"2013","unstructured":"Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013;31(3):177\u201384.","journal-title":"Trends Biotechnol"}],"container-title":["Journal of Epidemiology and Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44197-026-00578-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-026-00578-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44197-026-00578-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:21:53Z","timestamp":1784769713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44197-026-00578-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["578"],"URL":"https:\/\/doi.org\/10.1007\/s44197-026-00578-z","relation":{},"ISSN":["2210-6014"],"issn-type":[{"value":"2210-6014","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,21]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the Institutional Review Board and\/or Independent Ethics Committee and local data protection agencies. Adherence to legal, regulatory, and other applicable guidelines (as mentioned in sub-Sect.\u00a0 2.4 \u201cEthics\u201d of this publication) ensured scientific integrity. Due to the retrospective nature of the study, patient informed consent was not required and not collected.","order":1,"name":"Ethics","label":"Ethics Approval and Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent to publish was not required or collected because all patient information was anonymised and aggregated, and the submission does not include personally identifiable images.","order":2,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AT, AK, KP, KKup, LJ, and NM are employees of Pfizer and may hold stock\/stock options with Pfizer. AP is a former employee of Pfizer. AMO, JLMG, JLM, KKum, SB, TF, and VE declare no conflicts of interest. Micron Research Ltd. have received funding from Pfizer for data management, statistics and authoring of the CSR on the CODAR study. AG and RK have received honoraria or consultation fees from Micron Research Ltd. in the last three years, which are related to the submitted work. AS has received institutional grants or research support from Pfizer for the submitted study-related activities. AW has received honoraria or consultation fees from Medtronic. RFC has received honoraria or consultation fees from Pfizer, MSD, and Biomerieux, and institutional grants or research support from Pfizer. YP has received honoraria or consultation fees from Pfizer. MA has received honoraria or consultation fees from Pfizer, Merk and Shionogi.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"96"}}